News

Coronavir is one of the first medicine, both in Russia and globally, directly targeting the virus rather than merely addressing the...
read more...
September 17
Olokizumab is the first Russian original biologic for treatment of rheumatoid arthritis and also the first global direct inhibitor of...
read more...
September 14
The interim analysis of randomized Phase III clinical trial of Coronavir (favipiravir) has been published  in the peer-reviewed scientific...
read more...
August 10
R-Pharm Group announces positive results of CREDO 2, a pivotal global (1648 patients in 18 countries) Phase III clinical study of IL-6...
read more...
July 2
R-Pharm Holding, LLC (Headquarters: Moscow, Russia; Chairman: Alexey Repik, hereinafter R-Pharm) and Canon Medical Systems Corporation...
read more...
June 22
R-Pharm Group of Companies successfully registered Artlegia (olokizumab), a novel drug for treatment of rheumatoid arthritis in the first...
read more...
May 29
R-Pharm JSC has obtained official permission to conduct clinical trial in Russia to evaluate the efficacy and safety of radotinib for...
read more...
May 28
Deltyba® (delamanid) —an essential medicine according to the World Health Organization [1]—is now available in Russia for...
read more...
May 25
March 29, 2020 – R-Pharm Group has filed its first international patent application regarding biotech medicine that binds viral particles...
read more...
March 30
Considering COVID-19 pandemic, R-Pharm Group has taken the following measures to achieve better health protection of R-Pharm employees and...
read more...
March 24